Transformed chimpanzee lymphocytes were examined to determine whether they would support the replication of hepatitis B virus. After 5 months, no hepatitis B virus, hepatitis B surface antigen, or antibody to hepatitis B surface antigen was detected.
Although the viral etiology of hepatitis B has been firmly established and much progress has been made recently in the biophysical definition of the antigenic components of hepatitis B virus (HBV; 3, 4, 5, 6, 15), attempts to replicate this agent in a variety of in vitro cell culture systems have not to date been successful. Several recent studies have suggested that a surface antigenic component of HBV, now designated hepatitis B surface antigen (HBS Ag), may have some effect on the transformation of lymphocytes in vitro (1, 9, 12, 13) . Lymphocytes have been shown to support growth of several viral pathogens (11, 14) . However, there have been no reports to date on the ability of transformed lymphocytes to support replication of HBV. Since the cause of hepatitis B virus infection of chimpanzees resembles that seen in humans (2, 10) Cultures from all sources transformed in 4 to 6 weeks. Growth medium was RPMI 1640 (Grand Island Biological Co., Grand Island, N.Y.) with 1% L-glutamine, 20% inactivated fetal calf serum and 1 mg of neomycin per ml. Maintenance medium was identical to growth medium except RPMI 1629 was used. The cultures were split 1:2 twice weekly. At biweekly intervals before and after transformation several methods were used for examining the lymphocytes over a period of 5 months. Also, transformed lymphocyte cultures from normal chimpanzees and chronic carriers were inoculated with a serum of known hepatitis B infectivity (MS-2; 8) and examined periodically.
Radioimmunoassay (Ausria-Abbott Laboratories) for HB. 
